NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity falls 18.9% from a year ago

Total equity stood at $631.42M at the end of Q2 FY2026, down 18.9% from a year earlier and down 5.1% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.

Context

  • Total equity amounted to 89.6% of total assets at the end of Q2 FY2026, down 5.9 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -18.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$631.42M-5.1% QoQ
Last fiscal yearDec 2025
$683.43M-9.8% YoY
Year agoJun 2025
$778.5M-18.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.9%——
1 year-9.8%——
3-year CAGR+16.7%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
683.43M USD
Year-over-year change
-9.8%
4-year CAGR
+86.4%

Total Equity vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -18.9% is the 6th highest of 9, against a peer median of -4.3%.
  • Total equity amounts to 89.6% of total assets for NAMS, versus a peer median of 75.2%.
NAMS Competitors
Total Equity for NAMS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DNLIDenali Therapeutics Inc.Jun 2026$835.18M USD-18.7%-0.9%72.1%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$753.74M USD+127.0%-3.6%95.8%
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$631.42M USD-18.9%+16.7%89.6%
MDGLMadrigal Pharmaceuticals, Inc.Jun 2026$523.72M USD-24.7%+45.1%42.1%
SEPNSepterna, Inc.Sep 2026$427.93M USD+10.1%—69.1%
VKTXViking Therapeutics, Inc.Jun 2026$408.32M USD-48.7%+63.8%78.2%
BIOABioAge Labs, Inc.Mar 2026$379.12M USD+21.1%—95.3%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$87.48M USD-43.8%-28.0%65.5%
ATHEAlterity Therapeutics LimitedDec 2025A$54.21M AUD+596.3%+6.1%95.3%
Peer median (excluding NAMS) —-4.3%+2.6%75.2%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.38M467.73M340.45M771.74M490M
Short-term Investments00062.45M146.24M
Net Receivables5.51M01.88M21.31M23.15M
Inventory00000
Other Current Assets(627.81K)2.07M001.32M
Total Current Assets66.96M477.98M346.79M863.41M675.7M
Property, Plant & Equipment (Net)216.08K154K101K673K568K
Goodwill00000
Intangible Assets0208K170K534K407K
Long-term Investments138.02M0000
Tax Assets00000
Other Non-current Assets(137.2M)156K35K092.61M
Total Non-current Assets1.03M518K306K1.21M93.58M
Total Assets67.99M478.5M347.1M864.62M769.28M
Account Payables7.07M11.85M16.92M4.74M8.97M
Short-term Debt0000136K
Tax Payables00000
Deferred Revenue008.94M6.01M3.99M
Other Current Liabilities018.02M15.96M91.03M72.69M
Total Current Liabilities11.24M36.06M49.9M106.92M85.79M
Long-term Debt000066K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)001.02M00
Other Non-current Liabilities012.31M7.79M00
Total Non-current Liabilities126.24K12.37M8.81M202K66K
Total Liabilities11.36M48.43M58.7M107.12M85.85M
Common Stock128.51K10.06M10.17M13.44M14.28M
Retained Earnings(39.44M)(140.04M)(316.97M)(558.57M)(762.39M)
Accumulated OCI672.13K4.42M4.42M4.47M4.79M
Other Stockholders Equity00000
Minority Interest00000
Total Equity56.63M430.07M288.39M757.5M683.43M
Total Debt186.51K126K60K448K202K
Net Debt(60.19M)(467.6M)(340.39M)(771.3M)(489.8M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.